RXST250117P32500
- 1.10
- 0.000.00%
RxSight Newsroom
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $46
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $46
Needham Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $43
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $35 to $70
RxSight Is Maintained at Equal-Weight by Wells Fargo
Stifel Maintains Hold on RxSight, Lowers Price Target to $35
RxSight Analyst Ratings
Needham Reiterates Buy on RxSight, Maintains $66 Price Target
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $35 to $70
Needham Reiterates Buy on RxSight, Announces $66 Price Target
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Health Catalyst (HCAT) and Amicus (FOLD)
BTIG Sticks to Its Buy Rating for RxSight (RXST)
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $60
Analysts' Top Healthcare Picks: RxSight (RXST), Pacific Biosciences (PACB)
Stifel Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $40
Hold Rating Issued Amidst Rising Competition and Market Uncertainty for RxSight
Stifel Downgrades RxSight to Hold, Lowers Price Target to $40
Wells Fargo Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $42
RxSight Analyst Ratings
UBS Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $52